Article Text

PDF
PP 055
DO WE HAVE A CONSENSUS TO APPLY MODEL-BASED AMINOGLYCOSIDE THERAPY: A REVIEW OF POPULATION PHARMACOKINETIC MODELS
  1. Guo-Xiang Hao1,
  2. Sophie Teng2,
  3. Evelyne Jacqz-Aigrain3,
  4. Wei Zhao4
  1. 1Department of Clinical Pharmacy, School of Pharmaceutical sciences, Shandong University, Jinan, China
  2. 2Department of Pediatric Pharmacology and Pharmacogenetics, Clinical Investigation Center CIC1426, Hôpital Robert Debré, Université Paris Diderot, Paris, France
  3. 3Department of Pediatric Pharmacology and Pharmacogenetics, Clinical Investigation Center CIC1426, Hôpital Robert Debré, Université Paris Diderot, Paris, France
  4. 4Department of Clinical Pharmacy, School of Pharmaceutical sciences, Shandong University, Jinan, China; Department of Pediatric Pharmacology and Pharmacogenetics, Clinical Investigation Center CIC1426, Hôpital Robert Debré, Université Paris Diderot, Paris, France; Department of Pharmacy, Qianfoshan Hospital Affiliated to Shandong University, Shandong University, Jinan, China

Abstract

Background and Objective Aminoglycosides remain the standard antibiotic therapy for Gram-negative infections in both adults and children. The pharmacokinetic modeling approach has been widely used to evaluate aminoglycosides therapy. The aim of the present study is to review the published population pharmacokinetic models of commonly used aminoglycosides (gentamycin, amikacin and tobramycin), in order to determine if there was a consensus to apply model-based personalized aminoglycoside therapy in routine clinical practice.

Methods The bibliographic search was performed electronically using PubMed on 30th January 2015, following the search strategy: “((population Pharmacokinetics) OR (Pharmacokinetic modeling)) AND (gentamycin OR gentamicin OR amikacin OR tobramycin)”.

Results A total of 49 articles were identified. Persistent variabilities exist in terms of structure model; typical pharmacokinetic parameters and identified covariates.

Conclusion A pharmacokinetic meta-analysis is required to evaluate the study-related factors influencing the pharmacokinetics of aminoglycosides. A clinical evaluation of pharmacokinetic model of aminoglycosides is required to demonstrate its clinical utility.

  • ESDP

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.